🏢
🌐 Entity
Ixekizumab
Medication used to treat autoimmune diseases
📊 Rating
3 news mentions · 👍 0 likes · 👎 0 dislikes
📌 Topics
- Pharmaceutical innovation (2)
- Clinical Trials (1)
- Pharmaceutical Innovation (1)
- Psoriatic Arthritis Treatment (1)
- Combination Therapy (1)
- Treatment efficacy (1)
- Market impact (1)
- Combination therapy (1)
- Chronic disease treatment (1)
🏷️ Keywords
Eli Lilly (3) · Taltz (3) · Zepbound (3) · Psoriasis (2) · Combination therapy (2) · Psoriatic Arthritis (1) · Phase 3b Trial (1) · Obesity (1) · Pharmaceutical Innovation (1) · Clinical Results (1) · Clinical trial (1) · Biologic treatment (1) · Pharmaceutical economy (1) · Weight loss (1) · Clinical study (1) · Pharmaceutical innovation (1)
📖 Key Information
Ixekizumab, sold under the brand name Taltz, is an injectable medication for the treatment of autoimmune diseases. Chemically, it is a form of a humanized monoclonal antibody. The substance acts by binding interleukin 17A and neutralizing it, reducing inflammation.
📰 Related News (3)
-
-
-
🇺🇸 Lilly's Zepbound and Taltz improve psoriasis symptoms, drive weight loss in study
Eli Lilly said on Wednesday the combined use of its weight-loss drug Zepbound with psoriasis treatment Taltz showed better results in a late-stage st...
🔗 Entity Intersection Graph
People and organizations frequently mentioned alongside Ixekizumab:
-
Eli Lilly · 3 shared articles -
Tirzepatide · 3 shared articles -
Psoriasis · 2 shared articles -
🌐
Combination therapy · 1 shared articles
-
Weight loss · 1 shared articles -
Obesity · 1 shared articles -
Psoriatic arthritis · 1 shared articles